drugset / Trial / NCT02073812
Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects
Phase 1
Completed
26 enrolled
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
NaSingle-groupOpen-labelTreatment
Summary
RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.
Timeline
- Start
- 2014-02
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RPX2014 | Small molecule | — | Intravenous |
| Subject | Vaborbactam | Small molecule | — | Intravenous |
Indications
No indication recorded.